The Safety of Erythropoiesis-Stimulating Agents for the Treatment of Anemia Resulting from Chronic Kidney Disease.

about

The Safety of Erythropoiesis-Stimulating Agents for the Treatment of Anemia Resulting from Chronic Kidney Disease.

Item

http://www.wikidata.org/entity/Q38740871

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

The Safety of Erythropoiesis-S ...... g from Chronic Kidney Disease.

@en

type

Item

label

The Safety of Erythropoiesis-S ...... g from Chronic Kidney Disease.

@en

prefLabel

The Safety of Erythropoiesis-S ...... g from Chronic Kidney Disease.

@en

P1476

The Safety of Erythropoiesis-S ...... g from Chronic Kidney Disease.

@en

P2093

Nicolas Roberto Robles

http://www.w3.org/2001/XMLSchema#string

P2860

Erythropoietin-mediated protection in kidney transplantation: nonerythropoietic EPO derivatives improve function without increasing risk of cardiovascular events

Normalization of hemoglobin level in patients with chronic kidney disease and anemia

Epoetin Beta

Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis.

Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients.

Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature.

Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience.

Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia.

Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes.

Iron, inflammation, dialysis adequacy, nutritional status, and hyperparathyroidism modify erythropoietic response.

P304

421-431

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

meta-analysis

P356

10.1007/S40261-016-0378-Y

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-02-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

295246103

http://www.w3.org/2001/XMLSchema#string

P698

26894799

http://www.w3.org/2001/XMLSchema#string